Novel agents may positively impact chemotherapy and transplantation in subsets of diffuse large B-cell lymphoma

Parastoo B. Dahi, Craig Moskowitz, Sergio A. Giralt, Hillard M. Lazarus

Research output: Contribution to journalReview article

Abstract

Introduction: Molecular and biologic heterogeneity in diffuse large B-cell lymphoma (DLBCL) has resulted in a broad range of clinical outcomes. While standard frontline chemoimmunotherapy cures majority of patients with DLBCL, treatment failure in certain DLBCL subsets remains high. Prognosis in these patients is dismal. Therefore, optimization of front-line therapy, as well as development of more effective salvage treatments, is an unmet medical need. Areas covered: This article reviews the treatment advances in DLBCL with novel and targeted agents that are aimed to improve efficacy especially in those with high-risk features. Expert opinion: Incorporation of novel therapies such as immunomodulatory agents and Bruton tyrosine kinase (BTK) inhibitors in the treatment of higher-risk DLBCL subgroups have shown to be effective; however, confirmatory data are required to change the standard of care. While autologous chimeric antigen receptor (CAR) T-cell therapy targeting CD19-positive B-cells have revolutionized the outcomes of refractory DLBCL, the complexity of its production, post-infusion care, and the associated cost, currently has limited its use to select academic centers in the US. A multitude of other targeted agents and combinations as well as cellular and immunotherapeutic agents are under investigation.

Original languageEnglish (US)
Pages (from-to)407-418
Number of pages12
JournalExpert Review of Hematology
Volume12
Issue number6
DOIs
StatePublished - Jun 3 2019

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Transplantation
Drug Therapy
B-Lymphocyte Subsets
Salvage Therapy
Antigen Receptors
Autoantigens
Expert Testimony
Therapeutics
Standard of Care
Cell- and Tissue-Based Therapy
Treatment Failure
B-Lymphocytes
T-Lymphocytes
Costs and Cost Analysis

Keywords

  • allogeneic transplant
  • Autologous transplant
  • CAR T cell
  • checkpoint blockade
  • diffuse large B-cell lymphoma
  • large cell lymphoma
  • lymphoma immunotherapy
  • novel agents
  • transplant

ASJC Scopus subject areas

  • Hematology

Cite this

Novel agents may positively impact chemotherapy and transplantation in subsets of diffuse large B-cell lymphoma. / Dahi, Parastoo B.; Moskowitz, Craig; Giralt, Sergio A.; Lazarus, Hillard M.

In: Expert Review of Hematology, Vol. 12, No. 6, 03.06.2019, p. 407-418.

Research output: Contribution to journalReview article

Dahi, Parastoo B. ; Moskowitz, Craig ; Giralt, Sergio A. ; Lazarus, Hillard M. / Novel agents may positively impact chemotherapy and transplantation in subsets of diffuse large B-cell lymphoma. In: Expert Review of Hematology. 2019 ; Vol. 12, No. 6. pp. 407-418.
@article{e987b7f9723649b48864ff51e36a5407,
title = "Novel agents may positively impact chemotherapy and transplantation in subsets of diffuse large B-cell lymphoma",
abstract = "Introduction: Molecular and biologic heterogeneity in diffuse large B-cell lymphoma (DLBCL) has resulted in a broad range of clinical outcomes. While standard frontline chemoimmunotherapy cures majority of patients with DLBCL, treatment failure in certain DLBCL subsets remains high. Prognosis in these patients is dismal. Therefore, optimization of front-line therapy, as well as development of more effective salvage treatments, is an unmet medical need. Areas covered: This article reviews the treatment advances in DLBCL with novel and targeted agents that are aimed to improve efficacy especially in those with high-risk features. Expert opinion: Incorporation of novel therapies such as immunomodulatory agents and Bruton tyrosine kinase (BTK) inhibitors in the treatment of higher-risk DLBCL subgroups have shown to be effective; however, confirmatory data are required to change the standard of care. While autologous chimeric antigen receptor (CAR) T-cell therapy targeting CD19-positive B-cells have revolutionized the outcomes of refractory DLBCL, the complexity of its production, post-infusion care, and the associated cost, currently has limited its use to select academic centers in the US. A multitude of other targeted agents and combinations as well as cellular and immunotherapeutic agents are under investigation.",
keywords = "allogeneic transplant, Autologous transplant, CAR T cell, checkpoint blockade, diffuse large B-cell lymphoma, large cell lymphoma, lymphoma immunotherapy, novel agents, transplant",
author = "Dahi, {Parastoo B.} and Craig Moskowitz and Giralt, {Sergio A.} and Lazarus, {Hillard M.}",
year = "2019",
month = "6",
day = "3",
doi = "10.1080/17474086.2019.1596793",
language = "English (US)",
volume = "12",
pages = "407--418",
journal = "Expert Review of Hematology",
issn = "1747-4086",
publisher = "Expert Reviews Ltd.",
number = "6",

}

TY - JOUR

T1 - Novel agents may positively impact chemotherapy and transplantation in subsets of diffuse large B-cell lymphoma

AU - Dahi, Parastoo B.

AU - Moskowitz, Craig

AU - Giralt, Sergio A.

AU - Lazarus, Hillard M.

PY - 2019/6/3

Y1 - 2019/6/3

N2 - Introduction: Molecular and biologic heterogeneity in diffuse large B-cell lymphoma (DLBCL) has resulted in a broad range of clinical outcomes. While standard frontline chemoimmunotherapy cures majority of patients with DLBCL, treatment failure in certain DLBCL subsets remains high. Prognosis in these patients is dismal. Therefore, optimization of front-line therapy, as well as development of more effective salvage treatments, is an unmet medical need. Areas covered: This article reviews the treatment advances in DLBCL with novel and targeted agents that are aimed to improve efficacy especially in those with high-risk features. Expert opinion: Incorporation of novel therapies such as immunomodulatory agents and Bruton tyrosine kinase (BTK) inhibitors in the treatment of higher-risk DLBCL subgroups have shown to be effective; however, confirmatory data are required to change the standard of care. While autologous chimeric antigen receptor (CAR) T-cell therapy targeting CD19-positive B-cells have revolutionized the outcomes of refractory DLBCL, the complexity of its production, post-infusion care, and the associated cost, currently has limited its use to select academic centers in the US. A multitude of other targeted agents and combinations as well as cellular and immunotherapeutic agents are under investigation.

AB - Introduction: Molecular and biologic heterogeneity in diffuse large B-cell lymphoma (DLBCL) has resulted in a broad range of clinical outcomes. While standard frontline chemoimmunotherapy cures majority of patients with DLBCL, treatment failure in certain DLBCL subsets remains high. Prognosis in these patients is dismal. Therefore, optimization of front-line therapy, as well as development of more effective salvage treatments, is an unmet medical need. Areas covered: This article reviews the treatment advances in DLBCL with novel and targeted agents that are aimed to improve efficacy especially in those with high-risk features. Expert opinion: Incorporation of novel therapies such as immunomodulatory agents and Bruton tyrosine kinase (BTK) inhibitors in the treatment of higher-risk DLBCL subgroups have shown to be effective; however, confirmatory data are required to change the standard of care. While autologous chimeric antigen receptor (CAR) T-cell therapy targeting CD19-positive B-cells have revolutionized the outcomes of refractory DLBCL, the complexity of its production, post-infusion care, and the associated cost, currently has limited its use to select academic centers in the US. A multitude of other targeted agents and combinations as well as cellular and immunotherapeutic agents are under investigation.

KW - allogeneic transplant

KW - Autologous transplant

KW - CAR T cell

KW - checkpoint blockade

KW - diffuse large B-cell lymphoma

KW - large cell lymphoma

KW - lymphoma immunotherapy

KW - novel agents

KW - transplant

UR - http://www.scopus.com/inward/record.url?scp=85066825188&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066825188&partnerID=8YFLogxK

U2 - 10.1080/17474086.2019.1596793

DO - 10.1080/17474086.2019.1596793

M3 - Review article

C2 - 30884247

AN - SCOPUS:85066825188

VL - 12

SP - 407

EP - 418

JO - Expert Review of Hematology

JF - Expert Review of Hematology

SN - 1747-4086

IS - 6

ER -